Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AXSM

AXSM - Axsome Therapeutics Inc Stock Price, Fair Value and News

$185.28-2.74 (-1.46%)
Market Closed

33/100

AXSM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

33/100

AXSM

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$148.77

Target 3M

$174.8

Target 6M

$164.39

AXSM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXSM Price Action

Last 7 days

-2.0%

Last 30 days

23.0%

Last 90 days

39.2%

Trailing 12 Months

80.8%

AXSM RSI Chart

AXSM Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AXSM Valuation

Market Cap

9.3B

Price/Earnings (Trailing)

-40.69

Price/Sales (Trailing)

16.64

EV/EBITDA

-42.77

Price/Free Cashflow

-92.12

AXSM Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$148.77

Target 3M

$174.8

Target 6M

$164.39

AXSM Fundamentals

AXSM Revenue

Revenue (TTM)

561.3M

Rev. Growth (Yr)

63.22%

Rev. Growth (Qtr)

13.96%

AXSM Earnings

Earnings (TTM)

-229.5M

Earnings Growth (Yr)

26.89%

Earnings Growth (Qtr)

1.55%

AXSM Profitability

EBT Margin

-41.05%

Return on Equity

-311.32%

Return on Assets

-34.3%

Free Cashflow Yield

-1.09%

AXSM Investor Care

Shares Dilution (1Y)

4.02%

Diluted EPS (TTM)

-4.67

AXSM Alerts

  • 4 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025432.2M495.0M561.3M0
2024251.0M291.5M338.5M385.7M
2023144.6M182.5M223.4M270.6M
202200050.0M
20210000
20200000
201900287.1K356.9K
2018209.7K212.3K214.8K217.4K
2017000207.1K
20161.8M1.4M914.0K474.3K
20140002.2M
Get all data in R, Python etc through our Historical Stock Data APIs

About Axsome Therapeutics Inc

AXSM
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that is in Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial of for treating attention-deficit/hyperactivity disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.
 CEO
 WEBSITEaxsome.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES422

Axsome Therapeutics Inc Frequently Asked Questions

AXSM is the stock ticker symbol of Axsome Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Axsome Therapeutics Inc is 9.34 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AXSM's fair value in chart for subscribers.

The fair value guage provides a quick view whether AXSM is over valued or under valued. Whether Axsome Therapeutics Inc is cheap or expensive depends on the assumptions which impact Axsome Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AXSM.

As of Wed Jan 28 2026, AXSM's PE ratio (Price to Earnings) is -40.69 and Price to Sales (PS) ratio is 16.64. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AXSM PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Axsome Therapeutics Inc has provided 0.372 (multiply by 100 for percentage) rate of return.